InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.15 -0.82%

-$0.02 today

Market cap
$169.47M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 1.99M

Average 1.80M

IFRX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

InflaRx N.V.NASDAQ: IFRX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Context

  • Net margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of -109340.2% for the fiscal year ending Dec 2026, up from -155582.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-155582.1%-127797.1 pp YoY
LTMMar 2026
-146303.9%-111837.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-127186.1 pp—
1 year-127797.1 pp+46241.8 pp+174039.0 pp
3 years—-54049.5 pp—
5 years+155199.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-155582.1%
Year-over-year change
-127797.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How IFRX compares with its peers on the latest reported figures

  • IFRX's LTM Mar 2026 net margin of -146303.9% is the lowest of the 6 companies compared; the peer median is -5668.6%.
  • Its year-over-year change of -111837.5 pp is the lowest of 5, against a peer median of -4039.1 pp.
IFRX Competitors Peer median
Net Margin for IFRX and competitors
Company Period LTM level YoY 3-year change
STROSutro Biopharma, Inc.LTM Mar 2026-154.2% +214.9 pp-10.6 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4987.4% -3454.4 pp+10754.8 pp
IMAImageneBio IncFY2025-5668.6% -4623.8 pp-5228.3 pp
ATYRaTyr Pharma, Inc.LTM Mar 2026-36857.4% —-38572.9 pp
CNTBConnect Biopharma Holdings LimitedFY2025-86687.5% -86627.5 pp—
IFRXInflaRx N.V.LTM Mar 2026-146303.9% -111837.5 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding IFRX) -5668.6%-4039.1 pp-2619.4 pp

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.